A unifying feature across many of the chronic conditions targeted by GLP-1 medicines, including CVD, CKD, MASLD, osteoarthritis, PAD, and obstructive sleep apnea, is dysregulated inflammation, occurring frequently in the context of insulin resistance and obesity
The high-MW fractions form a transient occlusive layer on the surface during recovery, holding water and reducing transepidermal water loss in the 24-to-48-hour post-procedure window where the barrier is briefly compromised
The prevention of oxidative stress improve asthmatic inflammation
Members with genetic predisposition to lower baseline GLP-1 pathway activity may particularly benefit from dietary GLP-1 activators like allulose when combined with targeted medication therapy
The insertion of selenocysteine (Sec) during translation involves a unique set of specialized translational cofactors, including a Sec-specific elongation factor, a tRNA Sec that recognizes the UGA codon, and RNA binding proteins, such as SBP2 (SECIS binding protein 2) that bind to stem-loop structures in the 3-untranslated region of the selenoprotein transcripts denoted selenocysteine incorporation sequence or SECIS (for review see [64, 65])
